<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084511</url>
  </required_header>
  <id_info>
    <org_study_id>1320.13</org_study_id>
    <secondary_id>2013-003580-62</secondary_id>
    <nct_id>NCT02084511</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain</brief_title>
  <official_title>Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the effectiveness of BI 1026706 powder for reconstitution of an oral solution
      compared to placebo and the relative effectiveness compared to Celecoxib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted sum of pain intensity difference (PID) from 0 to 8 hours post drug administration (SPID0-8h)</measure>
    <time_frame>up to 8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted total pain relief (PAR) from 0 to 8 hours (TOTPAR0-8h)</measure>
    <time_frame>up to 8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted sum of PID from 0 to 2 hours (SPID0-2h)</measure>
    <time_frame>up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to meaningful pain relief</measure>
    <time_frame>up to 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first dose of rescue medication</measure>
    <time_frame>up to 10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>BI 1026706 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1026706 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1026706 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1026706 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 solution</intervention_name>
    <description>Placebo to BI 1026706 solution</description>
    <arm_group_label>Placebo reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 solution</intervention_name>
    <description>Placebo to BI 1026706 solution</description>
    <arm_group_label>BI 1026706 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <description>BI 1026706</description>
    <arm_group_label>BI 1026706 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 tablet</intervention_name>
    <description>Placebo to BI 1026706 tablet</description>
    <arm_group_label>BI 1026706 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 tablet</intervention_name>
    <description>Placebo to BI 1026706 tablet</description>
    <arm_group_label>Placebo reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 solution</intervention_name>
    <description>Placebo to BI 1026706 solution</description>
    <arm_group_label>Celecoxib reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <description>BI 1026706</description>
    <arm_group_label>BI 1026706 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706 tablet</intervention_name>
    <description>Placebo to BI 1026706 tablet</description>
    <arm_group_label>BI 1026706 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib capsule</description>
    <arm_group_label>Celecoxib reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the investigator's assessment, as based on the following
             criteria: a complete medical history including a physical examination, vital signs
             (Blood Pressure,Pulse Rate), 12-lead electrocardiogram, and clinical laboratory tests

          2. Age 18 to 55 years (incl.)

          3. Body Mass Index 18.5 to 29.9 kg/m2 (incl.)

          4. Patients scheduled for removal of one mandibular third molar with partial or complete
             bony impaction. If medically indicated, the ipsilateral third molar in the upper jaw
             could also be removed;

          5. Surgery will be conducted under local anaesthesia using 12% lidocaine (with
             epinephrine). Intravenous sedations and general anaesthetics are not permitted.

          6. Reliable, cooperative, and of adequate intelligence to record the requested
             information on the analgesic questionnaire form

          7. Examined by the attending oral surgeon or physician and medically cleared to
             participate in the study

          8. Scheduled to undergo a qualifying surgical procedure

          9. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          1. Any finding in the medical examination (including Blod Pressure, Pulse Rate or
             electrocardiogram) deviating from normal and judged clinically relevant by the
             investigator

          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic
             blood pressure greater than 90 mm Hg

          3. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          4. Any evidence of a concomitant disease judged clinically relevant by the investigator

          5. Acute local infection at the time of surgery that could confound the post-surgical
             evaluation

          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          7. Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1320.13.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

